HOME
SEARCH
RSS FEED
SUBSCRIBE
Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor Cells
Case ID:
TAB-875
Web Published:
12/6/2022
Description:
This invention relates to diphtheria toxin fusion proteins comprising a diphtheria toxin (DT) cell-killing component and a cell-binding component such as granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL-2), or epidermal growth factor (EGF). Receptors for the latter three materials are present on many types of cancer cells; therefore, these fusion proteins bind preferentially to these cancer cells. A key feature is that these toxins are altered so as to require activation by a cell-surface protease that is overexpressed on many types of cancers. Examples of such proteases include matrix metalloproteinases and urokinase plasminogen activator. Consequently, these novel cytotoxins kill tumors expressing receptors for either GM-CSF, IL-2, or EGF along with the cell-surface protease. Because killing requires the presence of both a receptor and a cancer-cell enriched protease, and few normal tissues contain both, there is less toxicity to normal cells. Thus, a larger amount of the agent may be used for cancer therapy without inducing side effects. In other words, these cytotoxins have a higher therapeutic index than toxins that are targeted to cells using a single strategy.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Activation_of_Recombinant_Diphtheria _Toxin_Fusion_Proteins_by_Specific_Proteases_Highly_Expressed_on_the_Surface _of_Tumor_Cells
Category(s):
Licensing
Oncology
Therapeutics
Bookmark this page
Download as PDF
For Information, Contact:
Vladimir Knezevic
Senior Advisor for Commercial Evaluations
NIH Technology Transfer
vlado.knezevic@nih.gov
Inventors:
Stephen Leppla
Shihui Liu
Manuel Osorio
Jennifer Avallone
Keywords:
CBXXXX
CXXXXX
DIPHTHERIA
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum